Clene Inc

Clene Inc has a market capitalization of $83.04 million and a price-to-book ratio of 19.47, indicating a high valuation relative to its book value. The company's liquidity position is characterized by a current ratio of 1.23, suggesting it has sufficient short-term assets to cover its short-term liabilities, but not by a large margin. The debt-to-equity ratio of 6.36 indicates a high level of leverage, with long-term debt amounting to $27.12 million against total equity of $4.26 million.

The company's profitability is weak, with a net loss of $11.08 million and an operating loss of $9.23 million. Return on equity is negative at -2.5985, and return on assets is also negative at -0.2458, indicating that the company is not generating returns that exceed its cost of capital. Gross profit of $57.00 million is offset by high operating expenses, leading to a significant net loss.

Clene Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. The company's revenue of $73.00 million is modest, and there is no indication of multiple revenue streams or geographic regions contributing to this figure.

Looking ahead, the company is expected to continue facing financial challenges. The operating cash flow is negative at $7.08 million, and free cash flow is also negative at $10.67 million. Capital expenditures are minimal at $11,000, suggesting limited investment in physical assets. The company's outlook for the current fiscal year is not explicitly provided, but the negative cash flows and high debt levels indicate a challenging growth trajectory.

The risk assessment for Clene Inc highlights medium liquidity risk and low dilution risk. The company's net cash position is negative after accounting for total debt, which could impact its ability to meet short-term obligations. The dilution risk is low, with no significant dilution potential identified in the basic shares outstanding. The company's high leverage and negative cash flows are key risk factors that could affect its financial stability.

Recent events and disclosures indicate that Clene Inc is actively engaged in clinical trials and research and development activities. The company has a mean price target of $30.40 from analysts, with a median price target of $30.00, suggesting a positive outlook from the investment community. However, the high price targets are not supported by current financial performance, and the company has not received any strong-buy recommendations from analysts.

Analysts project 421.9% upside to a mean price target of $30.40, signaling strong institutional confidence in future growth.

Free cash flow improved 34.6% year-over-year to -$24.7 million, indicating a meaningful reduction in cash burn rates.

Net income loss narrowed 33.6% year-over-year to -$26.2 million, demonstrating progress in controlling operational expenses relative to prior periods.

Long-term debt decreased to $15.8 million in FY-1, suggesting active balance sheet management and reduced leverage obligations.

Operating income improved 30.7% year-over-year to -$23.1 million, reflecting better cost efficiency despite continued operational losses.

The company carries high credit risk and a debt-to-equity ratio of 6.36, indicating significant financial leverage and solvency concerns.

Net margin of -151.8% ranks in the bottom quartile of the biotechnology cohort, showing extreme profitability inefficiency compared to peers.

A current ratio of 0.83 suggests potential liquidity constraints, as current assets are insufficient to cover short-term liabilities.

Return on equity stands at -2.59, placing the company in the bottom quartile of its peer group for capital efficiency.

Revenue $77.0k, −15,4% YoY; Operating income +15,5% YoY.

• ▍Revenue $77.0k, −15,4% YoY
• ▍Operating income +15,5% YoY
• ▍Net income +31,9% YoY
• ▍Free cash flow +32,3% YoY
• ▍Net margin -11981.8%

Revenue $15.0k, −82,8% YoY; Operating income +27,7% YoY.

• ▍Revenue $15.0k, −82,8% YoY
• ▍Operating income +27,7% YoY
• ▍Net income −9,9% YoY
• ▍Free cash flow −11,1% YoY
• ▍Net margin -58513.3%

Revenue $27.0k, −70,3% YoY; Operating income +20,7% YoY.

• ▍Revenue $27.0k, −70,3% YoY
• ▍Operating income +20,7% YoY
• ▍Net income −9,3% YoY
• ▍Free cash flow −10,7% YoY
• ▍Net margin -27477.8%

Revenue $81.0k, +11,0% YoY; Operating income +55,9% YoY.

• ▍Revenue $81.0k, +11,0% YoY
• ▍Operating income +55,9% YoY
• ▍Net income +93,2% YoY
• ▍Free cash flow +96,8% YoY
• ▍Net margin -927.2%

Revenue $91.0k; Operating income -$8.9M.

• ▍Revenue $91.0k
• ▍Operating income -$8.9M
• ▍Net margin -14889.0%

Revenue $87.0k; Operating income -$7.8M.

• ▍Revenue $87.0k
• ▍Operating income -$7.8M
• ▍Net margin -9179.3%

Revenue $91.0k; Operating income -$7.4M.

• ▍Revenue $91.0k
• ▍Operating income -$7.4M
• ▍Net margin -7456.0%

Revenue $73.0k; Operating income -$9.2M.

• ▍Revenue $73.0k
• ▍Operating income -$9.2M
• ▍Net margin -15178.1%

Revenue $200.0k, −41,5% YoY; Operating income +30,7% YoY.

• ▍Revenue $200.0k, −41,5% YoY
• ▍Operating income +30,7% YoY
• ▍Net income +33,6% YoY
• ▍Free cash flow +34,6% YoY
• ▍Net margin -13086.5%

Revenue $342.0k, −47,7% YoY; Operating income +17,8% YoY.

• ▍Revenue $342.0k, −47,7% YoY
• ▍Operating income +17,8% YoY
• ▍Net income +20,4% YoY
• ▍Free cash flow +21,5% YoY
• ▍Net margin -11520.5%

Revenue $654.0k, +38,3% YoY; Operating income +16,3% YoY.

• ▍Revenue $654.0k, +38,3% YoY
• ▍Operating income +16,3% YoY
• ▍Net income −65,5% YoY
• ▍Free cash flow −41,2% YoY
• ▍Net margin -7569.4%

Revenue $473.0k, −34,6% YoY; Operating income +1,9% YoY.

• ▍Revenue $473.0k, −34,6% YoY
• ▍Operating income +1,9% YoY
• ▍Net income −207,2% YoY
• ▍Free cash flow −236,8% YoY
• ▍Net margin -6325.2%